All In Biotech

Drug Trial Radar · NCT06644781

A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 510 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

510

Planned (sponsor's estimate)

Start

Mar 27, 2025

Primary completion

Jun 1, 2028

Study completion Nov 1, 2029

Sponsor

Lead sponsor
Daiichi SankyoDaiichi Sankyo (DSNKY)
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Oct 16, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd) in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have experienced disease progression following treatment with a platinum-based systemic therapy and an immune checkpoint inhibitor (ICI) compared with investigator's choice of chemotherapy (ICC).

Conditions

  • Esophageal Squamous Cell Carcinoma

Interventions

  • Ifinatamab deruxtecanDrug

    Intravenous administration

  • DocetaxelDrug

    Intravenous administration

  • PaclitaxelDrug

    Intravenous administration

  • Irinotecan hydrochloride (HCl)Drug

    Intravenous administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: From the date of randomization to the date of death due to any cause, up to approximately 54 months

Locations

168 sites in 17 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Hospital

    Phoenix, Arizona · Recruiting

  • Providence Medical Foundation

    Fullerton, California · Recruiting

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • Univ of California Irvine College of Medicine

    Orange, California · Recruiting

  • Henry Ford Health System

    Detroit, Michigan · Recruiting

  • Mayo Clinic Rochester

    Rochester, Minnesota · Recruiting

  • MidAmerica Cancer Care - American Oncology Partners

    Kansas City, Missouri · Recruiting

  • Morristown Medical Center

    Morristown, New Jersey · Recruiting

  • Maimonides Cancer Center

    Brooklyn, New York · Recruiting

  • Penn State University Milton S. Hershey Medical Center

    Hershey, Pennsylvania · Recruiting

  • Baptist Cancer Center

    Memphis, Tennessee · Recruiting

  • SCRI Oncology Partners

    Nashville, Tennessee · Recruiting

  • John Peter Smith Hospital

    Fort Worth, Texas · Recruiting

  • Virginia Cancer Specialists

    Fairfax, Virginia · Recruiting

  • Institut Jules Bordet

    Brussels, Belgium · Recruiting

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium · Recruiting

  • Antwerp University Hospital

    Edegem, Belgium · Recruiting

  • Universitair Ziekenhuis Gent

    Ghent, Belgium · Recruiting

  • UZ Leuven

    Leuven, Belgium · Recruiting

  • Chu de Liege

    Liège, Belgium · Recruiting

  • Anyang Cancer Hospital

    Anyang, China · Recruiting

  • Beijing Cancer Hospital

    Beijing, China · Recruiting

  • Jilin Cancer Hospital

    Changchun, China · Recruiting

  • The First Hospital of Jilin University

    Changchun, China · Recruiting

  • Changzhou Cancer Hospital

    Changzhou, China · Recruiting

  • Sichuan cancer hospital

    Chengdu, China · Recruiting

  • West China Hospital Sichuan University

    Chengdu, China · Recruiting

  • Fujian Cancer Hospital

    Fuzhou, China · Recruiting

  • The First Affiliated Hospital Zhejiang University School of Medicine

    Hangzhou, China · Recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, China · Recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, China · Recruiting

  • Anhui Provincial Cancer Hospital

    Hefei, China · Recruiting

  • The First Affiliated Hospital of Fujian Medical University

    Hefei, China · Recruiting

  • The Second Hospital of Anhui Medical University

    Hefei, China · Recruiting

  • Jieyang Peoples Hospital

    Jieyang, China · Recruiting

  • Jinan Central Hospital

    Jinan, China · Recruiting

  • Shandong Cancer Hospital

    Jinan, China · Recruiting

  • Affiliated Hospital of Jining Medical University

    Jining, China · Recruiting

  • Linyi Cancer Hospital

    Linyi, China · Recruiting

  • The First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, China · Recruiting

Showing 40 of 168 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.